Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
03.07. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
17.06. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
17.06. | Azitra, Inc.: Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome | 117 | PR Newswire | Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site
Trial is 50% enrolled... ► Artikel lesen | |
AZITRA Aktie jetzt für 0€ handeln | |||||
14.05. | Azitra GAAP EPS of -$0.23 | 1 | Seeking Alpha | ||
13.05. | Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates | 117 | PR Newswire | BRANFORD, Conn., May 13, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
13.05. | Azitra, Inc. - 8-K, Current Report | 11 | SEC Filings | ||
13.05. | Azitra, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
02.05. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
29.04. | Azitra, Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
24.04. | Azitra, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
24.04. | Azitra secures funding deal for dermatology treatments | 1 | Investing.com | ||
24.04. | Azitra sichert Finanzierungsvereinbarung für Dermatologie-Behandlungen | 1 | Investing.com Deutsch | ||
26.02. | Maxim Group cuts Azitra stock price target to $2 from $3, retains Buy rating | 6 | Investing.com | ||
25.02. | Azitra reports FY results | 2 | Seeking Alpha | ||
24.02. | Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates | 159 | PR Newswire | BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
24.02. | Azitra, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
20.02. | Azitra, Inc. - 8-K, Current Report | - | SEC Filings | ||
06.02. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.02. | Azitra announces pricing of $930,000 registered direct offering | 5 | Seeking Alpha | ||
04.02. | Azitra secures $930K in registered direct offering | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,416 | +4,39 % | Aixtron, Evotec, Hugo Boss, Renk Group, Suss MicroTec, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 33,610 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 25,420 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,280 | 0,00 % | Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia | Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition... ► Artikel lesen | |
PROKIDNEY | 3,720 | 0,00 % | Pre-market Movers: Basel Medical Group, SOBR Safe, ProKidney, RxSight, Mustang Bio | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green Basel Medical Group Ltd (BMGL) is up over 88% at... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 19,570 | 0,00 % | Structure Therapeutics Inc. - 8-K, Current Report | ||
QIAGEN | 41,390 | +0,28 % | Qiagen: Gewinn soll zulegen | Ende Juli gibt es von Qiagen die Zahlen zum zweiten Quartal. Große Überraschungen erwarten die Analysten der Deutschen Bank dabei nicht. Die Daten sollen auf Höhe der Prognose liegen. Qiagen rechnet... ► Artikel lesen | |
COGENT BIOSCIENCES | 11,100 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | ||
NUVALENT | 84,73 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
BEAM THERAPEUTICS | 21,150 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 41,620 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
ARCELLX | 69,86 | 0,00 % | Piper Sandler maintains Overweight rating on Arcellx stock amid CAR-T safety study | ||
IMMUNOVANT | 18,590 | 0,00 % | Goldman Sachs nimmt Berichterstattung über Immunovant mit "Neutral"-Rating wieder auf | ||
ARCUTIS BIOTHERAPEUTICS | 15,910 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
KYMERA THERAPEUTICS | 44,910 | 0,00 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen |